|
|
|
| Research progress of gastrointestinal flora and tumor chemotherapy drugs |
| TIAN Cheng1 YUAN Anlong2 |
1.School of Medicine, Wuhan University of Science and Technology, Hubei Province, Wuhan 430065, China;
2.Department of Gastroenterology, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Hubei Province, Xiaogan 432000, China |
|
|
|
Abstract The microbiome consists of symbiotic bacteria and other microorganisms present in host epithelial barriers. Microflora plays an important role in maintaining local homeostasis and systematically regulating physiological functions such as metabolism, hematopoiesis, inflammation and immunity. Microbiota are also involved in the occurrence, development and spread of cancer in epithelial barriers and sterile tissues. Gastrointestinal microbes are involved not only in cancer, but also in cancer prevention and chemotherapy. This article reviews the relationship between gastrointestinal microecology and tumor and chemotherapy.
|
|
|
|
|
|
[1] Costello EK，Stagaman K，Dethlefsen L，et al. The application of ecological theory toward an understanding of the human microbiome [J]. Science，2012，336（6086）：1255-1262.
[2] Bosch TC，McFall-Ngai MJ. Metaorganisms as the new frontier [J]. Zoology（Jena，Germany），2011，114（4）：185-190.
[3] Dzutsev A，Goldszmid RS，Viaud S，et al. The role of the microbiota in inflammation，carcinogenesis，and cancer therapy [J]. Eur J Immunol，2015，45（1）：17-31.
[4] Routy B，Le Chatelier E，Derosa L，et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors [J]. Science，2018，359（6371）：91-97.
[5] Gopalakrishnan V，Spencer CN，Nezi L，et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients [J]. Science，2018，359（6371）：97-103.
[6] Siegel RL，Miller KD，Jemal A，et al. Cancer statistics [J]. CA Cancer J Clin，2017，67：7-30
[7] Sun J，Kato I. Gut microbiota，inflammation and colorectal cancer [J]. Genes Dis，2016，3（2）：130-143.
[8] Viljoen KS，Dakshinamurthy A，Goldberg P，et al. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp，enterotoxigenic Bacteroides fragilis（ETBF）and clinicopathological features of colorectal cancer [J]. PLoS One，2015，10（3）：119-162.
[9] Flanagan L，Schmid J，Ebert M，et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development，colorectal cancer and disease outcome [J]. Eur J Clin Microbiol Infect Dis，2014，33（8）：1381-1390.
[10] Mima K，Nishihara R，Qian ZR，et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis [J]. Gut，2016，65（12）：1973-1980.
[11] Yang Y，Weng W，Peng J，et al. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-kappaB，and Up-regulating Expression of MicroRNA-21 [J]. Gastroenterology，2017，152（4）：851-866.
[12] Gur C，Ibrahim Y，Isaacson B，et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack [J]. Immunity，2015，42（2）：344-355.
[13] Yu T，Guo F，Yu Y，et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy [J]. Cell，2017，170（3）：548-563.
[14] Raisch J，Buc E，Bonnet M，et al. Colon cancer-associated B2 Escherichia coli colonize gut mucosa and promote cell proliferation [J]. World J Gastroenterol，2014，20（21）：6560-6572.
[15] Raisch J，Rolhion N，Dubois A，et al. Intracellular colon cancer-associated Escherichia coli promote protumoral activities of human macrophages by inducing sustained COX-2 expression [J]. Lab Invest，2015，95（3）：296-307.
[16] Arthur JC，Gharaibeh RZ，Muhlbauer M，et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer [J]. Nat Commun，2014，5：47-72.
[17] Cougnoux A，Dalmasso G，Martinez R，et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype [J]. Gut，2014，63（12）：1932-1942.
[18] Belkaid Y，Hand TW. Role of the microbiota in immunity and inflammation [J]. Cell，2014，157（1）：121-141.
[19] Goodwin AC，Destefano Shields CE，Wu S，et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis [J]. Proc Natl Acad Sci USA，2011，108（37）：15354-15359.
[20] Chung L，Thiele OE，Geis AL，et al. Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells [J]. Cell Host Microbe，2018，23（2）：203-214.
[21] Viljoen KS，Dakshinamurthy A，Goldberg P，et al. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between Fusobacterium spp，enterotoxigenic Bacteroides fragilis（ETBF）and clinicopathological features of colorectal cancer [J]. PLoS One，2015，10（3）：119-162.
[22] Huang JY，Lee SM，Mazmanian SK. The human commensal Bacteroides fragilis binds intestinal mucin [J]. Anaerobe，2011，17（4）：137-141.
[23] Yu YN，Fang JY. Gut Microbiota and Colorectal Cancer [J]. Gastrointest Tumors，2015，2（1）：26-32.
[24] Bik EM，Eckburg PB，Gill SR，et al. Molecular analysis of the bacterial microbiota in the human stomach [J]. Proc Natl Acad Sci USA，2006，103（3）：732-737.
[25] Khosravi Y，Dieye Y，Poh BH，et al. Culturable bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients [J]. ScientificWorldJournal，2014，2014：610421.
[26] Maldonado-Contreras A，Goldfarb KC，Godoy-Vitorino F，et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status [J]. ISME J，2011， 5（4）：574-579.
[27] Walker MM，Talley NJ. Review article：bacteria and pathogenesis of disease in the upper gastrointestinal tract--beyond the era of Helicobacter pylori [J]. Aliment Pharmacol Ther，2014，39（8）：767-779.
[28] Khatoon J，Rai RP，Prasad KN. Role of Helicobacter pylori in gastric cancer：Updates [J]. World J Gastrointest Oncol，2016，8（2）：147-158.
[29] Sitaraman R. Helicobacter pylori DNA methyltransferases and the epigenetic field effect in cancerization [J]. Front Microbiol，2014，5：115-126.
[30] Eun CS，Kim BK，Han DS，et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis，intestinal metaplasia，and gastric cancer using pyrosequencing methods [J]. Helicobacter，2014，19（6）：407-416.
[31] Lofgren JL，Whary MT，Ge Z，et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia [J]. Gastroenterology，2011，140（1）：210-220.
[32] Wang L，Zhou J，Xin Y，et al. Bacterial overgrowth and diversification of microbiota in gastric cancer [J]. Eur J Gastroenterol Hepatol，2016，28：261-266.
[33] Winter SE，Winter MG，Xavier MN，et al. Host-derived nitrate boosts growth of E.coli in the inflamed gut [J]. Science，2013，339（6120）：708-711.
[34] Wu H，Esteve E，Tremaroli V，et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes，contributing to the therapeutic effects of the drug [J]. Nat Med，2017，23（7）：850-858.
[35] Alexander JL，Wilson ID，Teare J，et al. Gut microbiota modulation of chemotherapy efficacy and toxicity [J]. Nat Rev Gastroenterol Hepatol，2017，14（6）：356-365.
[36] Haiser HJ，Turnbaugh PJ. Developing a metagenomic view of xenobiotic metabolism [J]. Pharmacol Res，2013，69（1）：21-31.
[37] Lehouritis P，Cummins J，Stanton M，et al. Local bacteria affect the efficacy of chemotherapeutic drugs [J]. Sci Rep，2015，5：145-154.
[38] Selwyn FP，Cui JY，Klaassen CD. RNA-Seq Quantification of Hepatic Drug Processing Genes in Germ-Free Mice [J]. Drug Metab Dispos，2015，43（10）：1572-1580.
[39] Daillere R，Vetizou M，Waldschmitt N，et al. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects [J]. Immunity，2016，45（4）：931-943.
[40] Viaud S，Saccheri F，Mignot G，et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide [J]. Science，2013，342（6161）：971-976.
[41] Iida N，Dzutsev A，Stewart CA，et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment [J]. Science，2013，342（6161）：967-970.
[42] Stein A，Voigt W，Jordan K. Chemotherapy-induced diarrhea：pathophysiology，frequency and guideline-based management [J]. Ther Adv Med Oncol，2010，2（1）：51-63.
[43] Wallace BD，Wang H，Lane KT，et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme [J]. Science，2010，330（6005）：831-835.
[44] Cario E. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity [J]. Curr Opin Support Palliat Care，2016，10（2）：157-164.
[45] Nigro G，Rossi R，Commere PH，et al. The cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut epithelial regeneration [J]. Cell Host Microbe，2014，15（6）：792-798.
[46] Chitapanarux I，Chitapanarux T，Traisathit P，et al. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients [J]. Radiat Oncol，2010，5：31-38.
[47] Wang Y，Luo X，Pan H，et al. Pharmacological inhibition of NADPH oxidase protects against cisplatin induced nephrotoxicity in mice by two step mechanism [J]. Food Chem Toxicol，2015，83：251-260. |
|
|
|
